chimeric antigen receptor t-cell therapy-City of Hope Medical Center-large B-cell lymphoma

This refers to a clinical trial protocol (IRB 22141) at City of Hope Medical Center evaluating the feasibility and safety of bridging radiation therapy prior to the infusion of commercial chimeric antigen receptor (CAR) T-cell therapies in patients with relapsed or refractory large B-cell lymphoma (LBCL). The study utilizes FDA-approved autologous CD19-targeted CAR T-cell products, such as axicabtagene ciloleucel (Yescarta), tisagenlecleucel (Kymriah), or lisocabtagene maraleucel (Breyanzi). Bridging radiation is administered to all sites of FDG-avid disease identified by PET/CT to control disease progression and symptoms during the period between leukapheresis and CAR T-cell infusion. The primary objective is to determine if this comprehensive bridging approach is safe and feasible without increasing toxicity.

Other names

Bridging Radiation Prior to CAR T-Cell Infusion in Large B-Cell Lymphoma